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Heart disease is a major cause of morbidity and pre-
mature mortality in the United States. Cardiovascular
disease affects 159 million Americans, ranks first among
all diagnostic categories necessitating hospitalizations,
and causes 1 in every 2.4 deaths (American Heart As-
sociation Web site). Although heart disease in developed
countries often arises through complex interactions be-
tween genetics, lifestyle choices, and environment, a con-
siderable fraction of cardiovascular disease—including
cardiomyopathy, arrhythmias, and congenital heart
malformations—are due to heritable, monogenic traits.
Application of human molecular genetic strategies to
elucidate the molecular etiologies of some of these con-
ditions has provided mechanistic insights into the cel-
lular events and signals that affect heart structure and
function (Milewicz and Seidman 2000).
Cardiomyopathy represents a diverse group of heart-
muscle disorders, which are further subdivided on the
basis of their anatomic and hemodynamic findings.
More than 80% of cardiomyopathies are classified as
dilated or congestive. These disorders increase both
myocardial mass and volume, such that, despite mod-
erate myocyte enlargement, or hypertrophy, the heart
appears thin walled and distended. Diminished contrac-
tile function is the critical hemodynamic feature of di-
lated cardiomyopathy, an abnormality that triggers com-
plex neurohumoral responses, which increase circulatory
volume so as to maintain cardiac output. Although such
events are initially compensatory, these responses ulti-
mately become maladaptive and contribute to clinical
deterioration and onset of heart failure. Only 50% of
patients with dilated cardiomyopathy survive 15 years
after diagnosis (Grogan et al. 1995); premature death
occurs from unmitigated pump failure and from co-
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morbidities such as thromboembolic events and arrhyth-
mias. Despite current strategies to aggressively manage
dilated cardiomyopathy, the disorder remains a common
cause of heart failure and a prevalent diagnosis in in-
dividuals referred for cardiac transplantation.
Diagnosis of dilated cardiomyopathy is often made
through noninvasive cardiac imaging, particularly
through two-dimensional echocardiography (fig. 1).
Measurements obtained throughout the cardiac cycle
provide systolic and diastolic dimensions that both index
the amount of chamber enlargement and provide an es-
timate of contractile function, through calculations of
the fractional shortening of heart muscle and the fraction
of blood ejected with each beat. Echocardiographic find-
ings of dilated cardiomyopathy usually prompt a search
for underlying causes of cardiac enlargement and di-
minished contractile function. Coronary artery disease,
viral myocarditis, thyroid disease, immunologic pro-
cesses, toxins (such as alcohol and the antineoplastic
agent danorubycin), and infiltrative processes (hemo-
chromatosis, sarcoidosis, or storage diseases) are well-
known causes of dilated cardiomyopathy. In many
instances, however, an underlying pathology is not dis-
covered, and the diagnosis of “idiopathic” dilated car-
diomyopathy ensues.
The histopathology of idiopathic dilated cardiomy-
opathy is usually nonspecific: degenerating myocytes
that exhibit mild-to-moderate hypertrophy without dis-
array (i.e., without misalignment of contiguous myo-
cytes), and an absence of inflammatory cells. Increased
interstitial fibrosis is often evident, but amounts can vary
quite considerably. Unique microscopic findings can help
to refine the more general diagnosis of dilated cardiomy-
opathy into a pathological subtype; for example, myo-
cyte loss and marked fibrofatty replacement with pref-
erential right-ventricular involvement indicates arrhyth-
mogenic right-ventricular dysplasia (Thiene et al. 1988).
Over the past two decades, there has been increased
recognition that many “idiopathic” dilated cardiomy-
opathies are familial. Although medical reports of fa-
milial cardiomegaly were published as early as 1948
(Evans 1948), a clinical estimate of prevalence came only
in 1992, when Michels and colleagues reported that
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Figure 1 Echocardiographic view of the normal and a dilated heart. Left panel, Parasternal long-axis view of a normal heart in end-
diastole, illustrating normal left-ventricular (LV) wall thickness (1.2 cm; curved lines) and cavity dimensions. A normal-sized left atrium (LA)
and aortic root (Ao) are shown on this view. Right panel, Dilated cardiomyopathy causing marked increases in the LV diastolic diameter (7.7
cm, arrowed line) and LA enlargement.
120% of individuals with dilated cardiomyopathy had
an affected first-degree relative (Michels et al. 1992).
Several large population-based studies have confirmed
these data and have delineated that dilated cardiomy-
opathy can be transmitted as autosomal (dominant and
recessive), X-linked, or mitochondrial traits (Keeling et
al. 1995; Gru¨nig et al. 1998; Mestroni et al. 1999). Not
only have these observations fostered molecular genetic
analyses aimed at the definition of disease-causing mu-
tations, but these studies have also altered clinical prac-
tice. Screening evaluations for clinically silent dilated
cardiomyopathy in family members at risk for inheriting
dilated cardiomyopathy has fostered early interventions
that both reduce symptoms and decrease the morbidity
and mortality associated with arrhythmias or thrombo-
embolic events. Although early initiation of treatments
may also retard progression and prolong the pretrans-
plantation phase of the disease, more-definitive therapies
for dilated cardiomyopathy await better mechanistic un-
derstandings of the molecular basis for this disease.
Clinical and Genetic Heterogeneity
There is considerable heterogeneity in the clinical fea-
tures of dilated cardiomyopathy resulting from a single
gene mutation. Age at disease onset ranges from early
childhood to late in senescence, although most cases of
genetic or acquired dilated cardiomyopathy become ap-
parent during the fourth or fifth decade of life. The nat-
ural history of disease can vary considerably with regard
to severity of symptoms and survival, even in affected
members of the same family. Family studies of dilated
cardiomyopathy sometimes demonstrate additional phe-
notypes that cosegregate with the disease (fig. 2); these
can be subtle and clinically unimportant or can pro-
foundly disturb another organ system. Additional car-
diac phenotypes (i.e., conduction-system disease and
mitral valve prolapse) and extracardiac findings (i.e.,
skeletal muscle abnormalities and sensorineural hearing
loss) have been described. Recognition of adjunct find-
ings in dilated cardiomyopathy was particularly impor-
tant for early genetic-mapping studies, since middle-age
onset of disease often constrained pedigree sizes and lim-
ited the number of families that were informative for
linkage analyses. Since adjunct phenotypes are some-
times expressed in advance of dilated cardiomyopathy,
these have been used as surrogate markers of cardiac
status, which have fostered the definition of multiple
genetic loci for familial dilated cardiomyopathy.
The most common mode of inheritance of familial
dilated cardiomyopathy is autosomal dominant (table
1). Incomplete penetrance is sometimes evident and pre-
sumably reflects the influence of modifying genes and
environment. Dominant loci that cause isolated dilated
cardiomyopathy have been found on chromosomes
1q32 (MIM 601494, Durand et al. 1995;MIM 191045,
Kamisago et al. 2000), 2q31 (MIM 604145, Siu et al.
1999), 5q33-34 (MIM 601411, Tsubata et al. 2000),
6q12-16 (MIM 605582, Sylvius et al. 2001), 9q13-22
(MIM 600884, Krajinovic et al. 1995), 14q11 (MIM
160760, Kamisago et al. 2000), 15q14 (MIM 102540,
Olson et al. 1998), and 15q22 (MIM 191010, Olson
et al. 2001). Dominant loci that cause dilated cardio-
myopathy in association with an additional phenotype
have been mapped to chromosome 10q21-23 (mitral
valve prolapse [MIM 601494, Bowles et al. 1996]),
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Figure 2 Diversity of phenotypes accompanying heritable dilated cardiomyopathy. A, Electrocardiographic tracings, revealing conduction-
system abnormalities in patients with dilated cardiomyopathy. Top, First-degree atrioventricular (AV) block with prolonged interval (horizonal
bar p .4 s) between atrial P wave (f) and subsequent ventricular QRS wave. Middle, Second-degree AV block; note that a QRS complex does
not follow the third or sixth P wave. Bottom, Presence of atrial fibrillation, with absence of P waves and irregular rhythm of ventricular QRS
complexes. B, Plantar (and palmar) keratosis, which accompanies dilated cardiomyopathy in Naxos syndrome. C, Audiogram showing normal
hearing (triangles) in comparison to sensorineural hearing loss in patients with dilated cardiomyopathy due to a mutation at chromosome 6q23-
24. White circles () and crosses (#) denote sound transmitted through air into the right and left ear, respectively. Note that hearing loss is
symmetric and affects air and bony (black circles [●]) transmission of sound.
chromosomes 1p1-q21, 2q14-22, and 3p22-25 (con-
duction-system disease [MIM 150330, Fatkin et al.
1999; MIM 604288, Jung et al. 1999; MIM 601154,
Olson et al. 1996]), chromosomes 2q35 and 6q23 (mus-
cular dystrophies [MIM 126560, Li et al. 1999; MIM
602067, Messina et al. 1997]), and chromosome 6q23-
24 (sensorineural hearing loss [MIM 605362, Scho¨n-
berger et al. 2000]). Dominant loci for arrhythmogenic
right-ventricular dysplasia reside on chromosomes 1q42
(MIM 600996, Rampazzo et al. 1995), 2q32.1-32.2
(MIM 602087, Rampazzo et al. 1997), 3p23 (MIM
604400, Ahmad et al. 1998), 10p12-14 (MIM 604401,
Li et al. 2000), 14q12-22 (MIM 602086, Severini et al.
1996), and 14q23-24 (MIM 107970, Rampazzo et al.
1994) Little is known about recessive mutations that
cause dilated cardiomyopathy, with the exception of the
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Table 1
Loci with Dilated Cardiomyopathy as the Predominant Phenotype
Locus Trait Additional Phenotype Disease Gene
1q32 AD None Cardiac troponin T
1q32 AD None ?
2q31 AD None ?
5q33-34 AD None d-sarcoglycan
6q12-16 AD None ?
9q13-22 AD None ?
14q11 AD None Cardiac b myosin heavy chain
15q14 AD None Cardiac actin
15q22.1 AD None a-tropomyosin
10q21-23 AD Mitral valve prolapse ?
1p1-q21 AD Conduction disease Lamin A/C
2q14-q22 AD Conduction disease ?
3q22-25 AD Conduction disease ?
6q23 AD Conduction disease and skeletal myopathy ?
2q35 AD Skeletal myopathy Desmin
6q23-24 AD Sensorineural hearing loss ?
1q42-43 AD ARVD and exercise-induced ventricular tachycardia Cardiac ryanodine receptor
2q32.1-32.3 AD ARVD ?
3p23 AD ARVD ?
10p12-14 AD ARVD ?
14q12-22 AD ARVD ?
14q23-24 AD ARVD ?
6p24 AR Wooly hair and keratoderma Desmoplakin
17q21 AR ARVD, wooly hair, and keratoderma Plakoglobin
Xp21 X Skeletal myopathy Dystrophin
Xq28 X Short stature and neutropenia Tafazzin
mutation that causes Naxos syndrome (arrhythmogenic
right-ventricular dysplasia, wooly hair, and keratinosis),
which maps to chromosome 17q21 (MIM 601214,
Coonar et al. 1998), and a clinically related disorder
encoded on chromosome 6p24 (MIM 605676, Norgett
et al. 2000). Chromosome Xq28 mutations (Barth syn-
drome [MIM 302060, Bolhuis et al. 1991]) cause di-
lated cardiomyopathy in the context of neutropenia and
short stature. Specific dystrophin defects (Xp21) can
also lead to dilated cardiomyopathy with more modest
skeletal muscle pathology than typically occurs inDuch-
enne muscular dystrophy (MIM 302045, Towbin et al.
1993). In addition to disease loci in which cardiac phe-
notype predominates, many multisystem diseases and
neuromuscular disorders exhibit dilated cardiomyopa-
thy as one component of the phenotype (Kaplan and
Fontaine 2001).
Mechanisms of Human Dilated Cardiomyopathy
Definition of the genetic causes for some cardiac con-
ditions has provided mechanistic insights into heretofore
poorly understood disease processes. For example, the
discovery of the genetic basis for long-QT syndrome
showed that this enigmatic sudden-death syndrome is a
heritable disorder of cardiac ion channels (Keating and
Sanguinetti 2001); elucidation of the molecular basis for
“idiopathic” hypertrophic cardiomyopathy has also re-
defined this pathology as a disorder of the sarcomere
(Seidman and Seidman 2001). These paradigms initially
heightened expectations that genetic studies would also
provide a unified pathogenetic mechanism for “idio-
pathic” dilated cardiomyopathy. Instead, these studies
indicate a great diversity of genetic causes for dilated
cardiomyopathy. Although the number of disease genes
identified to date remains limited, and many more will
undoubtedly be defined, the current repertoire of mu-
tations that cause dilated cardiomyopathy suggest amul-
tiplicity of pathways (fig. 3) by which the heart can fail.
Deficits in Force Generation
Cardiac function is dependent on force production by
the sarcomere, the fundamental unit of contraction in
all muscle cells. Although many human mutations in the
protein constituents of the sarcomere have been identi-
fied, only recently have these deficits been recognized as
being associated with dilated cardiomyopathy. Missense
mutations in b cardiac myosin heavy chain and an in-
frame deletion of cardiac troponin T (Kamisago et al.
2000) cause autosomal dominant dilated cardiomyopa-
thy. Many previously reported defects in each of these
genes cause hypertrophic cardiomyopathy (a primary
myocardial disorder characterized by increased heart
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Figure 3 Schematic of the multiple mechanisms leading to dilated cardiomyopathy. Insufficiencies of force production and force trans-
mission, deficits of myocyte energy, and apoptosis or necrosis can each result in ventricular dilation and deficits in myocardial contraction. Note
that single gene mutations (inside circle) and some acquired causes (outside circle) of dilated cardiomyopathy perturb the same pathways. The
functional consequences of some mutations remain unknown.
mass and preserved contractile function). Recently, how-
ever, specific defects have been defined that produce
early-onset heart failure that occurs without associated
findings. Dilated cardiomyopathy due to a deletion in
cardiac troponin T is thought to disrupt calcium-sensi-
tive troponin C interactions that are critical for actin-
myosin ATPase activity. A decrease in this enzymatic
activity could reduce the energy needed to power sar-
comere contraction. The location of b cardiac myosin
missense mutations that cause dilated cardiomyopathy
suggests that these may also reduce contractile force.
Structural data (Rayment et al. 1993) indicate that one
mutation leads to a substitution of an amino acid in-
volved in tight binding of actin by myosin, an interaction
that is essential for initiation of the power stroke of
contraction. Another dilated-cardiomyopathy defect al-
ters a residue in one of several flexible joints of myosin
that undergo conformational changes during the con-
tractile cycle and that transmit movement and direc-
tionality throughout the thick filament.
Deficits in Force Transmission
Physiologic heart function requires that contractile force
generated by the sarcomere be effectively transmitted to
the extracellular matrix. Although little is known about
the precise biophysical mechanism by which this occurs,
multiple filamentous proteins found in muscle cells that
link the contractile apparatus to the sarcolemma are
thought to function in the propagation of force to the
extracellular matrix. Cardiac actin is centrally located
within the sarcomere, where it participates in force pro-
duction and is linked to cytoskeletal components that
transmit force. Two mutations in cardiac actin cause
early onset of autosomal dominant dilated cardiomy-
opathy without additional clinical phenotypes (Olson et
al. 1998). Since the location of actin missense mutations
alters amino acid residues involved in actin-cytoskele-
tal—rather than actin-myosin—interactions, the conse-
quence of actin mutations that cause dilated cardiomy-
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opathy is thought to be diminution of force transmission
from the sarcomere to the cytoskeleton.
Two missense mutations in a-tropomyosin were re-
cently reported (Olson et al 2001) that also cause dilated
cardiomyopathy. Each is located on the surface of the
molecule, in positions that may be involved in electro-
static interactions between a-tropomyosin and actin or
other thin-filament proteins. Diminished interactions
could disrupt the structural and/or functional integrity
of the thin filament and could impede force production
by the sarcomere or force transmission to the myocyte
cytoskeleton.
Intermediate-filament proteins, such as desmin, join
actin to the dystrophin-sarcoglycan complex, located
just beneath the plasma membrane of all muscle cells.
Components of the sarcoglycan complex also extend
outside of myocytes into the extracellular matrix. Mu-
tations in several of these molecules are widely recog-
nized as causes of skeletal muscular dystrophies—
degenerative muscle disorders that often exhibit some
myocardial involvement. Surprisingly, mutations in dys-
trophin, desmin, and d-sarcoglycan have also been iden-
tified in patients with dilated cardiomyopathy, in whom
there is either subclinical or no skeletal muscle involve-
ment (Muntoni et al. 1993; Li et al. 1999; Tsubata et
al. 2000). The probable mechanism by which these de-
fects cause the heart to fail is by ineffectual transmission
of force. However, why allelic mutations cause predom-
inant clinical disease in skeletal—versus cardiac—
muscle remains an unanswered question. The location
of a dystrophin mutation may influence the pattern of
muscle involvement; defects in promoter elements, 5′
gene deletions, and mid-rod mutations may appear to
more selectively affect heart muscle (Muntoni et al.
1993, 1997; Milasin et al. 1996).
Given the many proteins that participate in force
transmission, deficits in this pathway might be expected
to be a prevalent cause of dilated cardiomyopathy. So
far, only three genes coding for these proteins have been
analyzed, in small families and in sporadic cases. Anal-
yses of actin and desmin sequences (Tesson et al. 2000),
in 41 probands with familial disease and 22 sporadic
cases of dilated cardiomyopathy, identified no muta-
tions. A study of adult-onset dilated cardiomyopathy
(Arbustini et al 2000) identified only 13 dystrophin mu-
tations in 201 samples; in four individuals, familial
transmission of disease was evident. Another study, of
27 patients with dilated cardiomyopathy, reported no
dystrophin mutations (Michels et al. 1993).
Mutations in plakoglobin (also called “g-catenin”)
have been demonstrated to cause arrhythmogenic right-
ventricular cardiomyopathy with palmoplantar kera-
toderma (fig. 2B) and wooly hair (Naxos syndrome
[McKoy et al. 2000]). Mutations in desmoplakin lead
to a very similar phenotype (Norgett et al. 2000), al-
though with more-pronounced left-ventricular involve-
ment. These rare recessive syndromes share many his-
topathological features with autosomal dominant
arrhythmogenic right-ventricular dysplasia, including
myocyte death and prominent right-ventricular fibro-
fatty replacement. Both desmoplakin and plakoglobin
have critical functions in desmosomes and adherens
junctions, where intermediate filaments are anchored to
the plasmamembrane to create tight junctions with con-
tiguous cells. Since these junctions are presumed to be
important for overall organ function of the heart and
skin, a likely consequence of defective cell-cell junctions
in the heart would be impaired force propagation.
Understanding of the mechanism by which plakoglo-
bin defects cause disease has also been fostered by anal-
yses of plakoglobin-null mice (Bierkamp et al. 1996;
Ruiz et al. 1996); myocardium from these mutants has
decreased compliance, because of reduced cell-cell
adhesions. When the heart is subjected to mechanical
stress, the animals die of ventricular rupture. Whether
plakoglobin mutations are sufficient to promote myo-
cyte death or whether this occurs as a function of con-
stant mechanical stress is unknown.
Deficits in Energy Production
Recessive mutations in genes that encode transport pro-
teins or enzymes involved in cardiac fatty acid b-oxi-
dation can cause dilated cardiomyopathy (Roe and Ding
2001). Mitochondrial b-oxidation provides an impor-
tant source of energy during periods of fasting; defects
in this pathway damage the myocardium indirectly,
through an inadequate supply of energy, or directly,
owing to toxic effects of intermediary metabolites.
Intracellular accumulation of intermediary metabolites
(such as long-chain acylcarnitines) may be arrhythmo-
genic; these could account for the increased incidence of
sudden death associated with these disorders, relative to
other cardiac disorders.
Carnitine is required for entry of long-chain fatty ac-
ids into mitochondria, and carnitine deficiencies prevent
metabolism of long-chain fatty acids. Mutations in pro-
teins that participate in carnitine transport and metab-
olism are heritable causes of dilated cardiomyopathy
that are transmitted as recessive traits. Dilated cardio-
myopathy is also a feature of mutations in the organic
cation transporter protein, which transports carnitine
into cells; in translocase, which shuttles carnitine and
acylcarnitine into the mitochondria; and in carnitine
palmitoyltransferase II (Roe and Ding 2001), which cat-
alyzes carnitine derivatives into acyl-CoA. Cardiomy-
opathy can be the presenting manifestation of these car-
nitine-deficiency states, but skeletal muscle disease and
metabolic defects (hypoketotic hypoglycemia) are usu-
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ally evident. Cardiac function is normal in heterozygous
carriers.
Many of the reported human mutations in proteins
involved in b-oxidation are associated with hypertro-
phic—rather than dilated—cardiomyopathy. Notable
exceptions are defects in the mitochondrial trifunctional
protein that affect long-chain L-3-hydroxylacyl-CoA
protein (Brackett et al. 1995). These defects cause skel-
etal myopathy, dilated cardiomyopathy, and hepatic
steatosis.
Mutations in the mitochondrial genome result in mul-
tisystem pathologies with prominent neurologic, meta-
bolic, and cardiac phenotypes. The energy requirements
of these tissues are presumably more affected by deficits
in oxidative phosphorylation that result from mito-
chondrial mutations than are other organs. The car-
diomyopathy that accompanies most mitochondrial
mutations can be either hypertrophic or dilated, and
conduction-system abnormalities are seen frequently in
association with these pathologies. In addition to the
pleiotropic manifestations, cardiomyopathy due to
mitochondrial mutations (unlike that due to mutations
of mitochondrial proteins encoded within the nuclear
genome) are distinguished by matrilineal inheritance.
However, family studies indicate that heart involvement
in affected members varies considerably, presumably be-
cause of mitochondrial heteroplasmy. Further, since
mitochondrial mutations spontaneously accumulate
with physiologic aging (Melov et al. 1995), demonstra-
tion of the causal role of these defects in late-onset di-
lated cardiomyopathy is problematic (Ruppert and
Maisch 2000) and should require biochemical evidence
of altered oxidative phosphorylation in heart tissues.
Mutations with Unknown Mechanisms
Tafazzin (also called “G4.5”) is a protein of unknown
function, encoded at Xq28, that is mutated in Barth
syndrome, which is a triad of dilated cardiomyopathy,
neutropenia, and increased 3-methylglutaconicaciduria
(Bione et al. 1996). Several different transcripts that dif-
fer at their amino terminus and within a central domain
are produced from the tafazzin gene. Tafazzins belong
to a gene family of acyltransferases involved in phos-
pholipid biosynthesis; other structurally related proteins
have unknown functions (Neuwald 1997). Onset of
Barth syndrome occurs in infancy, and arrhythmias and
heart failure frequently accompany this neonatal dilated
cardiomyopathy. Cardiac pathology can vary consider-
ably in affected males, and ventricular noncompaction,
as well as cardiac fibroelastosis, have been described
(D’Adamo et al. 1997). Both heart morphology and
function in female carriers of tafazzin mutations is
normal.
Dominant mutations in the nuclear envelope proteins
lamin A and C cause progressive conduction-system dis-
ease and dilated cardiomyopathy (Fatkin et al. 1999).
Longitudinal evaluations of affected kindreds demon-
strate progressive prolongation of the normal delay in
electrical activation of the atrial and ventricular cham-
bers (fig. 2A); after many years of conduction-system
disease, the myocardium dilates, contractile function
decreases, and heart failure ensues. Although important
functions have been ascribed to lamin proteins, neither
the location of these molecules nor their known func-
tions provide insights into the mechanism by which con-
duction-system disease and cardiomyopathy occurs in
cases of lamin mutations. Lamin proteins A, C, and B2
are intermediate filament components of the nuclear
envelope, a multimeric structure that is associated
with the nucleoplasmic surface of the inner nuclear
membrane. These ubiquitously expressed proteins are
thought to contribute structural integrity to the nuclear
envelope and provide mechanical support for the nu-
cleus (Wilson et al. 2001). Lamins A and C undergo
phosphorylation that fosters depolymerization and dis-
assembly of the nucleus during mitosis; dephosphory-
lation of lamins contributes to the reassembly of the
nuclear membrane after cell division. Although their
functions in nondividing cells such as cardiac myocytes
are largely unknown, lamins A and C contain a chro-
matin-binding site and may participate in ordering of
the genome. They are also associated with nuclear
pores, suggesting a potential role in nuclear-cytoplasmic
trafficking. In muscle cells, lamins may also function to
reduce mechanical stresses imposed on the nucleus by
cyclical contractions; if mutations interfere with this
lamin function, the structural integrity of the nucleus
could be compromised, and premature myocyte death
could ultimately result.
Distinct mutations in lamin A/C can also lead to au-
tosomal dominant Emery-Dreifuss muscular dystrophy
(Bonne et al. 1999), to the related condition limb-girdle
muscular dystrophy (Muchir et al. 2000), and to fa-
milial partial lipodystrophy (Dunnigan type [Cao and
Hegele 2000; Shackleton et al. 2000; Speckman et al.
2000]), a disorder of adipocyte degeneration and pro-
found insulin-resistant diabetes. Despite marked differ-
ences in the predominant clinical phenotypes of these
allelic disorders, cardiac disease is an important com-
ponent of each disorder. Mice that have been engineered
to carry lamin A/C mutations also show features of each
human condition: mutant animals develop muscular
dystrophy and dilated cardiomyopathy and are devoid
of white fat (Sullivan et al. 1999).
Arrhythmogenic right-ventricular dysplasia (ARVD) is
a distinct morphological type of dilated cardiomyopathy
that is transmitted as an autosomal dominant trait and
is expressed with incomplete penetrance (Thiene et al.
2000). As in Naxos syndrome, the right ventricle is par-
256 Am. J. Hum. Genet. 69:249–260, 2001
ticularly prone to progressive myocardial atrophy in
ARVD. Left-ventricular involvement, although more
modest, is usually also present. Marked electrical insta-
bility is an important feature of ARVD and accounts
for the high incidence of sudden death associated with
this disorder. Although ARVD is infrequently diagnosed
in the United States, estimates from Italy indicate an
incidence of 6/10,000 individuals.
Six disease loci for ARVD have been mapped, but
only one disease gene has been identified. The cardiac
ryanodine receptor is encoded at 1q42; recently, mu-
tations were reported that cause exercise-induced ven-
tricular tachycardia and sudden death in individuals
with features of ARVD (Tiso et al. 2001). However,
cardiomyopathy has not been reported with other ry-
anodine-receptor mutations that are associated with ex-
ercise-induced ventricular tachycardia (Laitinen et al.
2001; Priori et al. 2001). Whether these data imply that
only specific ryanodine-receptor–gene mutations cause
ARVD or implicate functionally related molecules in
this cardiomyopathy remains an open question. The car-
diac ryanodine receptor is the main calcium-release
channel in the myocardial sarcoplasmatic reticulum and
fosters electrical excitation with mechanical contrac-
tion. Mechanisms by which mutations in this receptor
might produce the fibrofatty degeneration that typifies
ARVD may therefore include calcium-induced myocyte
apoptosis and/or necrosis.
Genetics of Acquired Dilated Cardiomyopathy
De novo mutations, incomplete penetrance, and small
family size can limit recognition of the contribution that
heritable gene mutations may have in the overall inci-
dence of dilated cardiomyopathy. Nevertheless, a sub-
stantial proportion of these clinical disorders is likely
acquired. Recent evidence suggests that similar mecha-
nisms by which single gene mutations cause dilated car-
diomyopathy may function in nonheritable forms of this
disease. Genetic defects in the dystrophin-glycoprotein
complex appear to cause hereditary dilated cardiomy-
opathy, through impairment of force transmission. A
comparable mechanism may account for the ventricular
dilation and dysfunction that can ensue after viral myo-
carditis, in that enteroviruses encode a protease that can
cleave the dystrophin-glycoprotein complex in model
systems (Badorff et al. 1999). Since nitric oxide has
been demonstrated to inhibit a coxsackieviral protease
through S-nitrosylation (Badorff et al. 2000), elucidation
of a definitive role for proteases in the pathogenicity of
dilated cardiomyopathy may foster the development
of novel therapeutics to prevent the cardiac dysfunction
associated with some viral infections.
Chronic ischemia that occurs from coronary-artery
atherosclerosis may be the most common cause of di-
lated cardiomyopathy. Despite this straightforward in-
citing event, it is unknown whether apoptosis, insuf-
ficient energy, or reduced contractile forces are the
primary triggers for ventricular dilation.
Animal Models of Dilated Cardiomyopathy
Many of the morphological and hemodynamic features
of dilated cardiomyopathy are represented in animal
models of this human disease. Characterization of ge-
netic models that arose from spontaneousmutations—or
that were produced through the introduction of germline
mutations by means of transgenic or recombinatorial
strategies—have helped elucidate the consequences of
mutations and provide insights into the downstream sig-
nals triggered by inciting events. Mouse gene mutations
that alter the muscle LIM protein (Arber et al. 1997),
desmin (Milner et al. 1996), and d-sarcoglycan (Nigro
et al. 1997) confirm that cytoskeletal dysfunction is one
cause of dilated cardiomyopathy. Deficits in myocyte en-
ergy and metabolism have been modeled by ablation of
a mitochondrial transcription factor (Tfam) in mice
(Wang et al. 1999). Animals deficient in lamin A/C (Sul-
livan et al. 1999) or in the bradykinin receptor B2
(Emanueli et al. 1999) also develop dilated cardiomy-
opathy, although the signaling pathways triggered by
these events remain unclear.
In addition to confirming the multiplicity of pathways
by which the heart can fail, studies of animal models
for dilated cardiomyopathy have sometimes uncovered
unexpected findings. For example, although both hu-
man and murine d-sarcoglycan mutations cause dilated
cardiomyopathy, the responses to these gene defects ap-
pear to be quite different. Mice lacking d-sarcoglycan
develop coronary-artery spasm, which results in myo-
cardial ischemia, necrosis, and, eventually, dilated car-
diomyopathy (Cohn et al. 2001). Administration of the
calcium-channel antagonist verapamil reduces coro-
nary-artery ischemia and improves cardiac function. An
important role for d-sarcoglycan in the biology of hu-
man coronary arteries has not been recognized. Human
mutations in this component of the dystrophin-associ-
ated protein complex have been reported (bothmissense
mutations in exon 6 and a 3-bp deletion in exon 9) to
cause dilated cardiomyopathy, but studies of the cor-
onary arteries from affected individuals have not indi-
cated ischemia (Tsubata et al. 2000). Rather, human
mutations are thought to alter heart function through
dominant negative influences on the dystrophin-sarco-
glycan complex, analogous to the mechanism by which
these cause skeletal muscular dystrophy. Whether these
distinct consequences of d-sarcoglycan mutations reflect
different mutations or unique functions of d-sarcoglycan
in human and murine hearts is unknown.
Important insights have also come from strategies
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aimed at complementation of dilated cardiomyopathy
deficits by genetic manipulation of models of disease.
Ablation of the muscle LIM protein (MLP [Arber et al.
1997]) in mice causes neonatal dilated cardiomyopathy.
However, if these mutant mice are bred with mice
deficient in the phospholamban gene (Minamisawa et
al. 1999), normal cardiac function is preserved. Phos-
pholamban functions as a physiologic inhibitor of
SERCA2a, an ATPase-dependent pump that restores cy-
tosolic calcium to the sarcoplasmic reticulum; ablation
of phospholamban would therefore enhance calcium
reuptake by the sarcoplasmic reticulum. Functional im-
provement, by abrogation of phospholamban function,
of hearts that are genetically predisposed to dilated car-
diomyopathy implicates calcium as a fundamental me-
diator of some of the pathophysiological components
of heart failure. These data raise the possibility that
pharmacological inhibition of phospholamban may en-
hance heart function in dilated cardiomyopathy.
A third insight about the pathogenetic mechanisms
of dilated cardiomyopathy comes from a recently de-
scribed model of ARVD, produced by ablation of the
a-actinin–associated LIM domain protein (ALP [Pashm-
foroush et al. 2001]). This protein colocalizes with a-
actinin and plakoglobin at the intercalated disc and
seems to play a role in the mechanical stability of the
cell-cell contacts in long myocardial fibers. ALP is al-
most exclusively expressed in the right ventricle, which
is concordant with the phenotype of a right-ventricular
dysfunction and dilatation, whereas the left-ventricular
function is only mildly depressed. Although features of
human ARVD are produced by this model, neither fi-
brofatty infiltrates nor spontaneous arrhythmias have
been observed in it. Human ALP maps to 4q35, a ge-
nomic location where ARVD loci have not been de-
scribed. Nevertheless, the intriguing similarities between
components of these phenotypes suggest that proteins
that are functionally related to ALP may be important
in human ARVD.
Conclusions
Dilated cardiomyopathy is often an insidiously progres-
sive disorder that relentlessly progresses toward heart
failure. Associated with high morbidity and mortality,
this disease produces substantial burdens on patients,
families, and health care economic systems. Better
understanding of the inciting events that cause dilated
cardiomyopathy, as well as elucidation of myocyte re-
sponses triggered by these events, have great potential
to improve quality of life, lengthen survival of affected
individuals, and reduce the need for cardiac transplan-
tation. Although heritable mutations are less common
than other causes of dilated cardiomyopathy, insights
gleaned frommolecular genetic studies provide some im-
mediate and many potential benefits for improving this
condition. For families with monogenic causes of dilated
cardiomyopathy, gene-based diagnosis has improved
presymptomatic recognition of the disease and has en-
abled early interventions. Further, these discoveries pro-
vide new paradigms for considering the many mecha-
nisms by which the heart can fail. Ultimately, these
understandings should provide new opportunities for the
targeting of therapeutic interventions.
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